Open AccessCutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma
Author(s) -
Robert H.I. Andtbacka,
Sanjiv S. Agarwala,
David W. Ollila,
Sigrun Hallmeyer,
Mohammed Milhem,
Thomas T. Amatruda,
John Nemunaitis,
Kevin J. Harrington,
Lisa Chen,
Mark Shilkrut,
Merrick I. Ross,
Howard L. Kaufman
Publication year - 2016
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/k6kh-g914
Subject(s) - medicine , melanoma , head and neck , granulocyte macrophage colony stimulating factor , stage (stratigraphy) , oncology , oncolytic virus , randomized controlled trial , surgery , cancer research , cytokine , cancer , biology , paleontology